Avanir Pharmaceuticals Inc (AVNR) financial statements (2023 and earlier)

Company profile

Business Address 20 ENTERPRISE
ALISO VIEJO, CA 92656
State of Incorp. DE
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2014
9/30/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments271,87055,259
Cash and cash equivalents271,87055,259
Receivables22,83112,526
Inventory, net of allowances, customer advances and progress billings799710
Inventory799710
Prepaid expense1,6311,391
Other current assets2,366991
Other undisclosed current assets1,320966
Total current assets:300,81771,844
Noncurrent Assets
Inventory, Noncurrent620784
Property, plant and equipment3,6311,593
Restricted cash and investments1,3041,304
Other noncurrent assets611554
Total noncurrent assets:6,1664,235
TOTAL ASSETS:306,98376,079
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities32,09325,561
Accounts payable6,7245,876
Accrued liabilities15,37011,909
Employee-related liabilities9,9997,776
Debt 7,943
Other undisclosed current liabilities 1,289
Total current liabilities:32,09334,792
Noncurrent Liabilities
Long-term debt and lease obligation 21,422
Long-term debt, excluding current maturities 21,422
Liabilities, other than long-term debt1,5011,393
Other liabilities1,5011,393
Total noncurrent liabilities:1,50122,815
Total liabilities:33,59457,607
Stockholders' equity
Stockholders' equity attributable to parent273,38918,472
Common stock1915
Additional paid in capital824,342518,992
Accumulated deficit(550,972)(500,536)
Total stockholders' equity:273,38918,472
TOTAL LIABILITIES AND EQUITY:306,98376,079

Income statement (P&L) ($ in thousands)

9/30/2014
9/30/2013
Revenues
(Revenue, Net)
115,02975,366
Cost of revenue
(Cost of Goods and Services Sold)
(3,522)(4,150)
Gross profit:111,50771,216
Operating expenses(161,373)(146,793)
Other undisclosed operating income3,5224,150
Operating loss:(46,344)(71,427)
Nonoperating income1252
Investment income, nonoperating2052
Other nonoperating expense(8)(0)
Interest and debt expense(4,101)(4,098)
Loss from continuing operations before income taxes:(50,433)(75,473)
Income tax expense(3)(3)
Net loss available to common stockholders, diluted:(50,436)(75,476)

Comprehensive Income ($ in thousands)

9/30/2014
9/30/2013
Net loss:(50,436)(75,476)
Comprehensive loss, net of tax, attributable to parent:(50,436)(75,476)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: